Eloralintide for Hepatic Insufficiency

This trial aims to evaluate how the drug Eloralintide (LY3841136) functions in individuals with varying levels of liver damage compared to those with healthy livers. Researchers will assess how the body absorbs and processes the drug and will document any side effects. The trial seeks participants with mild, moderate, or severe liver damage, as well as those without liver issues. Individuals with chronic liver problems for over six months may be suitable candidates. The study spans approximately 14 weeks, including a 5-night stay at a research center. As a Phase 1 trial, this research focuses on understanding the treatment's effects in people, offering participants the opportunity to be among the first to receive this new drug.

The trial information does not specify if you need to stop taking your current medications. It seems that participants with stable medical conditions and treatments that don't affect their health or the study can join, but it's best to discuss your specific medications with the study team.

Research shows that Eloralintide (LY3841136) has been tested in various situations. Most patients have found the treatment generally easy to handle, with few serious side effects reported. In earlier studies, researchers administered Eloralintide to individuals with different liver health statuses to observe absorption and metabolism.

Eloralintide is unique because it offers a targeted approach for treating hepatic insufficiency, a condition where the liver can't perform its normal functions. Unlike existing treatments that primarily focus on managing symptoms or complications, Eloralintide is administered subcutaneously and may directly influence liver function, potentially offering a more direct and efficient way to support liver health. Researchers are excited about its potential to address varying degrees of liver impairment—ranging from mild to severe—by adapting the treatment to individual needs, which could lead to more personalized and effective care options for patients.

Research shows that Eloralintide, also known as LY3841136, targets specific liver processes that might enhance its function. Although limited human data exists on its efficacy for liver issues, its mechanism suggests potential benefits. Early studies of similar treatments have shown promise in reducing liver fat and improving liver health. These findings offer hope that Eloralintide might aid those with liver damage, but further research is necessary to confirm its effectiveness. Participants in this trial will receive Eloralintide, with different arms examining its effects on varying levels of hepatic function, from normal to severe impairment.¹²³⁶⁷